Influence of Postmenopausal Hormone Replacement Therapy on an Estrogen Metabolite Biomarker of Risk for Breast Cancer

Abstract

Whether postmenopausal hormone-replacement therapy (HRT) increases the risk of breast cancer remains controversial, despite numerous epidemiological studies. We approached the question from a biochemical rather than an epidemiological direction - we hypothesized that if estrogen administration increases the risk of breast cancer, it should also alter a known estrogen biomarker of risk towards what has been observed in patients who already have breast cancer. The specific biomarker we studied was the ratio of the urinary excretion of two principal estradiol metabolites, 2-hydroxyestrone and 16α-hydroxyestrone, which is markedly decreased in women with breast cancer and women with familial risk for breast cancer. We studied 34 healthy postmenopausal women not on HRT and 19 women on HRT (Premarin 0.625 mg daily plus Provera, 2.5 mg daily, in women with a uterus and Premarin alone in women without a uterus); treatment duration ranged from 3 months to 15 years. We also studied four women with recently diagnosed, untreated breast cancer. The women with breast cancer showed a significantly lower 2-hydroxyestrone to 16α-hydroxyestrone ratio than control women on HRT (1.35 ± 0.13 vs. 2.71 ± 0.84; p < 0.0001). There was no significant difference in the metabolite ratio between healthy women on HRT and women not on HRT (2.82 ± 0.92 vs. 2.71 ± 0.84). There was no significant difference between women receiving Premarin alone and women receiving Premarin plus Provera (2.46 ± 0.84 vs. 3.13 ± 0.90), and neither differed significantly from women not on HRT (2.71 ± 0.84). The finding that the ratio of women on HRT was not decreased to or toward the ratio in women with breast cancer can be interpreted, we believe, as a suggestive item of biochemical evidence that HRT is not a risk for breast cancer.

Breast Cancer - Estrogens - Risk Factors

References

• 1 Greene R R, Brewer J I. Relation of sex hormones to tumors of the female reproductive system.  Am J Roentgenol Radiother. 1941;  45 426-445
• 2 Colditz G A, Stampfer M J, Willett W C, Hennekens C H, Rosner B, Speizer F E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women.  JAMA. 1990;  264 2648-2653
• 3 Gapstur S M, Potter J D, Sellers T A, Folsom A R. Increased risk of breast cancer with alcohol consumption in postmenopausal women.  Am J Epidemiol. 1992;  136 1221-1231
• 4 Steinberg K K, Thacker S B, Smith S J, Stroup D F, Zack M M, Flanders W D, Berkelman R L. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.  JAMA. 1991;  265 1985-1990
• 5 Grady D, Ernster V. Invited commentary: does postmenopausal hormone therapy cause breast cancer?.  Am J Epidemiol. 1991;  134 1396-1400
• 6 Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Conteras R, Bueno-Cavanillas A, Galnez-Vargas R. Menopausal hormone replacement therapy and breast cancer: a meta-analysis.  Obstet Gynecol. 1992;  79 286-294
• 7 Colditz G A, Egan K M, Stampfer M J. Hormone replacement therapy and risk of breast cancer: Results from epidemiological studies.  Am J Obstet Gynecol. 1993;  168 1473-1480
• 8 Dupont W D, Page D L. Therapy and breast cancer.  Arch Int Med. 1991;  151 67-72
• 9 Armstrong B K. Oestrogen therapy after the menopause-boon or bane?.  Med J Austral. 1988;  148 213-214
• 10 Gambrell R D Jr. Hormone replacement therapy and breast cancer risk.  Arch Fam Med. 1996;  5 341-348
• 11 Zumoff B. Does postmenopausal estrogen administration increase the risk of breast cancer? Contributions of animal, biochemical, and clinical investigative studies to a resolution of the controversy.  Proc Soc Exp Biol Med. 1998;  217 31-37
• 12 Ginsburg E L, Mello N K, Mendelson J H, Barbieri R L, Teoh S K, Rothman M, Gao X, Sholar J W. Effects of alcohol ingestion on estrogens in postmenopausal women.  JAMA. 1996;  276 1747-1751
• 13 Gapstur S M, Morrow M, Sellers T A. Hormone replacement therapy and risk of breast cancer with a favorable histology.  JAMA. 1999;  281 2091-2097
• 14 Writing Group for the Women's Health Institute . Risks and benefits of estrogen plus progestin in healthy postmenopausal women.  JAMA. 2002;  288 32-33
• 15 Schneider J, Kinne D, Fracchia A, Pierce V, Anderson K E, Bradlow H L, Fishman J. Abnormal oxidative metabolism of estradiol in women with breast cancer.  Proc Natl Acad Sci USA. 1982;  79 3047-3051
• 16 Bradlow H L, Hershcopf R, Martucci C, Fishman J. 16α-hydroxylation of estradiol: A possible risk marker for breast cancer.  Ann NY Acad Sci. 1986;  464 138-151
• 17 Suto A, Bradlow H L, Kubota T, Kitajima M, Wong G Y, Osborne M P, Telang N T. Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents.  Steroids. 1993;  58 215-219
• 18 Auburn K J, Woodworth C, DiPaolo J A, Bradlow H L. The interaction between HPV infection and estrogen metabolism in cervical carcinogenesis.  Int J Cancer. 1991;  49 867-869
• 19 Suto A, Bradlow H L, Kubota T, Kitajima M, Wong G Y, Osborne M P, Stelang N T. Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor-suppressing agents.  Steroids. 1993;  58 215-219
• 20 Telang N T, Suto A, Wong G Y, Osborne M P, Bradlow H L. Estrogen metabolite 16α-hydroxyestrone induces genotoxic damage and aberrant cell proliferation in mouse mammary epithelial cells in culture.  J Natl Cancer Inst. 1992;  84 634-638
• 21 Kabat G C, Chang C J, Sprano J A, Sepkovic D W, Hu X P, Khalil A, Rosenblatt R, Bradlow H L. Urinary estrogen metabolites and breast cancer. A case-control study.  Cancer Epidemiol Biomarkers Preven. 1997;  6 505-509
• 22 Bradlow H L, Sepkovic D W, Klug T, Osborne M P. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites.  Steroids. 1998;  63 406-413